Related references
Note: Only part of the references are listed.Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases
Antoine Petitcollin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis
Jeffrey S. Hyams et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring
Camille Lucidarme et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
Julien Kirchgesner et al.
GASTROENTEROLOGY (2018)
Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease
Tomer Greener et al.
INFLAMMATORY BOWEL DISEASES (2018)
Success and safety of high infliximab trough levels in inflammatory bowel disease
David Drobne et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration
David Ternant et al.
CLINICAL PHARMACOKINETICS (2018)
Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study
Xavier Roblin et al.
INFLAMMATORY BOWEL DISEASES (2017)
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission
Aurelien Amiot et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2016)
The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery
Cheryl Lau et al.
ANNALS OF SURGERY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
Nynne Nyboe Andersen et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
Nynne Nyboe Andersen et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011
Christine Rungoe et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety
KL Hyrich et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)